Antitumor effect of mSurvivin Thr34 → Ala in murine colon carcinoma when administered intravenously

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1156-1163

  Li, Hong Xia ^a,b   Zhao, Xin Yu ^b   Wang, Lian ^b   Wang, Yong Sheng ^b   Kan, Bin ^b   Xu, Jian Rong ^b   Li, Jiong ^b   Wen, Yan Jun ^b   Peng, Xing Chen ^b   Chen, Xiang ^b   Yan, Fei ^b   Ye, Bin ^b   Du, Xiao Bo ^b   Zhao, Ju Mei ^b   Yi, Tao ^a   Chen, Xian Cheng ^b   Du, Xiao Xia ^b   Wei, Yu Quan ^b   Zhao, Xia ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Adoptive cells transfer; Angiogenesis; Apoptosis; Cationic liposome; Cytotoxic T lymphocytes

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALANINE; CD31 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MUTANT PROTEIN; SURVIVIN; THREONINE; BIRC5 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; LIPOSOME; REPRESSOR PROTEIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SUBPOPULATION; CHROMIUM 51 RELEASE; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; COLON TUMOR; ENZYME IMMUNOASSAY; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); WESTERN BLOTTING;

ADOPTIVE TRANSFER; ALANINE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; GENE THERAPY; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITOR OF APOPTOSIS PROTEINS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; REPRESSOR PROTEINS; THREONINE;

EID: 79951771172     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9353-2     Document Type: Article

References (55)

1. Midgley R, Kerr D. Colorectal cancer. Lancet. 1999;353(9150):391-9. (Pubitemid 29088178)
2. + T cells in colorectal cancer patients. Cancer Res. 2003;63(15):4507-15. (Pubitemid 36957896)
3. Tsuruma T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med. 2004;2(1):19.
4. Reed JC, Bischoff JR. BIRinging chromosomes through cell division-and survivin' the experience. Cell. 2000;102(5):545-8.
5. Uren AG, et al. Survivin and the inner centromere protein IN-CENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000;10(21):1319-28.
6. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 2003;9(17):6523-33. (Pubitemid 38031841)
7. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 2003;9(7):2683-92. (Pubitemid 36842114)
8. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108(7):981-90. (Pubitemid 32946072)
9. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotech. 1997;15:647-52. (Pubitemid 27291165)
10. Brattain MG, Strobel-Stevens J, Find D, Webb M, Sarrif AM. Establishment of mouse colonic carcinoma with different metastatic properties. Cancer Res. 1980;40:2142-6. (Pubitemid 10082214)
11. Ben-Sasson SA, Sherman Y, Gavrieli Y. Identification of dying cells-in situ staining. Methods Cell Biol. 1995;46:29-39.
12. Blezinger P, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 1999;17(4):343-8. (Pubitemid 29166035)
13. Hameed A, Olsen KJ, Lee MK, Lichtenheld MG, Podack ER. Cytolysis by Ca-permeable transmembrane channels. Pore formation causes extensive DNA degradation and cell lysis. J Exp Med. 1989;169(3):765-77. (Pubitemid 19085819)
14. Jicha DL, Mulé JJ, Rosenberg SA. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med. 1991;174(6):1511-5.
15. + tumor-infiltrating lymphocytes. J Exp Med. 1991;173(3):647-58.
16. Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA. 1998;95:9482-7. (Pubitemid 28506257)
17. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8T cells in Qa-1-deficient mice. Nat Immunol. 2004;5:516-23. (Pubitemid 38660464)
18. Kawasaki H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91:2026-32. (Pubitemid 32476366)
19. Lee GH, et al. Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol. 2006;18:957-63.
20. Zhen HN, Zhang X, Hu PZ. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer. 2005;104:2775-83. (Pubitemid 41798288)
21. O'Connor DS, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 2000;156(2):393-8. (Pubitemid 30643793)
22. Tran J, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun. 1999;264(3):781-8.
23. Harfouche R, Hasséssian HM, Guo Y, et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res. 2002;64(1):135-47. (Pubitemid 34713240)
24. Papapetropoulos A, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem. 2000;275(13):9102-5. (Pubitemid 30185122)
25. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A. 2002;99(7):4349-54. Epub 2002 Mar. 26. (Pubitemid 34285988)
26. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000;60(17):4845-9.
27. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61(3):869-72. (Pubitemid 32175146)
28. Schmidt SM, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003;102(2):571-6. Epub 2003 Feb. 6. (Pubitemid 36841977)
29. Tsuruma T, et al. Clinical and immunological evaluation of antiapoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med. 2008;6:24.
30. Sumida SM, et al. Neutralizing antibodies and CD8 T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol. 2004;78(6):2666-73. (Pubitemid 38314325)
31. Sumida SM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174(11):7179-85. (Pubitemid 40705685)
32. Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther. 2008;16(9):1609-16. Epub 2008 Jul. 8.
33. Lusky M, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol. 1998;72(3):2022-32. (Pubitemid 28100756)
34. Morsy MA, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA. 1998;95(14):7866-71. (Pubitemid 28326032)
35. McCoy K, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J Virol. 2007;81(12):6594-604. Epub 2007 Apr. 11. (Pubitemid 46878063)
36. Barouch DH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004;172(10):6290-7. (Pubitemid 38621236)
37. Vogels R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77(15):8263-71. (Pubitemid 36871454)
38. Leen AM, et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroupspecific CD8+ T cells. Blood. 2004;104(8):2432-40. Epub 2004 Jul. 20. (Pubitemid 39331844)
39. Davis ME. Non-viral gene delivery systems. Curr Opin Biotechnol. 2002;13(2):128-31. (Pubitemid 34310371)
40. Dean Allison S, Thomas J. Anchordoquy. Lyophilization of nonviral gene delivery systems. In: Findeis MA, editors. Methods in molecular medicine, vol. 65: Nonviral vectors for gene therapy. Totowa, NJ: Humana Press Inc; 2001.
41. Peng XC, et al. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34->Ala mutant. J Exp Clin Cancer Res. 2008;27:46.
42. Chiba T, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer. 2004;91(9):1711-7. (Pubitemid 39546145)
43. Naito Y, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491-4. (Pubitemid 28376536)
44. Menon AG, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest. 2004;84(4):493-501. (Pubitemid 41656477)
45. Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg. 2004;91(4):469-75. (Pubitemid 38491119)
46. Koch M, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244(6):986-92. (Pubitemid 44808640)
47. + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186-92. Epub 2008 Dec. 8.
48. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself. Nat Immunol. 2005;6(4):345-52. (Pubitemid 41716771)
49. Wang RF. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum Immunol. 2008;69(11):811-4. Epub 2008 Sep. 24.
50. Somasundaram R, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 2002;62(18):5267-72. (Pubitemid 35024601)
51. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606-12. (Pubitemid 36182591)
52. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-4. Epub 2002 Sep. 19. (Pubitemid 35231542)
53. Dudley ME, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-57. (Pubitemid 46218728)
54. Antony PA, et al. CD8+ T cell immunity against a tumor/selfantigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174(5):2591-601. (Pubitemid 40279672)
55. Liu Y, et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol. 1997;15:167-73. (Pubitemid 27081784)